Is stem cell therapy FDA approved? For most treatments marketed for knee pain, back pain, Parkinson’s disease, peripheral neuropathy, and similar regenerative uses, the answer is no. The FDA has approved specific cellular and gene therapy products for specific medical conditions, but those approvals do not extend to the broad category of outpatient treatments commonly advertised as “stem cell therapy.”
That distinction matters. A treatment may involve cells, be offered by a licensed medical practice, or use equipment that has some form of FDA clearance without the treatment itself being FDA approved for the condition being treated.
For a broader introduction to the field, patients can review our Regenerative Medicine in Dallas Guide before comparing individual treatment claims.
The Short Answer Depends on the Product and the Condition
FDA approval is not granted to “stem cell therapy” as one broad category. Approval applies to a particular medical product for a particular indication.
Current FDA records include approved cellular and gene therapies for diseases such as sickle cell disease, certain cancers, inherited blood disorders, and rare genetic diseases. Some of these treatments involve hematopoietic stem or progenitor cells. CASGEVY, for example, is a cell-based gene therapy approved for specific sickle cell disease and transfusion-dependent beta-thalassemia indications. LENMELDY is made from a patient’s own genetically modified hematopoietic stem cells and is approved for specific forms of metachromatic leukodystrophy.
Those approvals should not be interpreted as FDA approval for injecting or administering stem cell products to treat arthritis, back pain, Parkinson’s disease, neuropathy, or other unrelated conditions.
A patient evaluating a treatment therefore needs a more specific question:
Has the exact product being offered received FDA approval for my exact medical condition?
That question is much harder to answer incorrectly with vague marketing language.
Why Older FDA Stem Cell Information Needs Context in 2026
Patients researching this subject may encounter an FDA consumer alert from 2020 stating that the only FDA-approved stem cell products consisted of blood-forming cells derived from umbilical cord blood. That page remains useful for its warnings about orthopedic and neurological uses, but the FDA’s broader cellular and gene therapy approvals have changed since the alert was published.
By September 2026, the FDA’s approved cellular and gene therapy list includes newer products such as CASGEVY, LENMELDY, LYFGENIA, and other cell-based therapies. These approvals remain narrow and indication-specific. They do not represent approval of general regenerative medicine treatments offered for musculoskeletal pain or common neurological conditions.
This is why statements such as “stem cells are FDA approved” can be technically misleading without additional context. Some cell-based medical products are approved. The specific treatment being advertised to a patient may not be.
What “FDA Approved” Actually Means
Several regulatory terms sound similar but mean very different things. Patients should understand the distinction before relying on a clinic’s website, advertisement, consent form, or sales conversation.
| Term | What Patients Should Understand |
|---|---|
| FDA approved or licensed | FDA reviewed a specific drug or biological product for specified indications under the applicable approval pathway. Approval for one condition does not automatically apply to another condition. |
| FDA cleared | Usually refers to a medical device that has gone through an applicable device clearance pathway. A cleared device does not automatically make a treatment performed with it FDA approved. |
| FDA registered | A company or tissue establishment may be required to register with FDA. Registration does not mean that its treatment has received FDA approval. |
| ClinicalTrials.gov listing | A study appearing in the federal clinical trial database does not mean the treatment has been proven effective or approved for routine marketing. |
| IND | An Investigational New Drug application can permit an investigational product to be studied under FDA oversight. An active IND is not the same as FDA marketing approval. |
| Section 361 HCT/P | Certain human cell or tissue products that satisfy specific regulatory criteria may be regulated solely under Section 361 and 21 CFR Part 1271 rather than going through premarket approval. That status should not be described as FDA approval. |
FDA specifically warns consumers that registration with the agency or appearance on ClinicalTrials.gov should not be used as proof that a regenerative medicine product is legally marketed or FDA approved.
FDA guidance also explains that certain human cells, tissues, and cellular and tissue-based products can qualify for regulation solely under Section 361 only when the applicable criteria are met, including requirements related to minimal manipulation and homologous use. Products that do not meet those criteria may be subject to additional drug, device, or biological product requirements, including premarket review.
Is Stem Cell Therapy FDA Approved for Knee Pain or Arthritis?
Patients with persistent knee pain often encounter advertisements suggesting that stem cells can rebuild cartilage, reverse arthritis, or eliminate the need for surgery. FDA approval does not support those broad claims.
FDA consumer information states that regenerative medicine therapies have not been approved for orthopedic conditions such as osteoarthritis, knee pain, hip pain, tendonitis, shoulder pain, disc disease, and related musculoskeletal problems.
That does not answer the separate scientific question of whether particular orthobiologic procedures are being researched or may have a role in selected patients. It means the treatment should not be presented as an FDA-approved stem cell treatment for knee arthritis when such an approval does not exist.
Someone trying to understand the diagnosis itself can review information about knee arthritis. The diagnosis matters because knee pain can arise from several structures, and treatment decisions should begin with identifying the actual cause rather than selecting a regenerative procedure first.
What About Back Pain and Disc Disease?
The same regulatory distinction applies to treatments advertised for back pain.
FDA explicitly includes back pain and disc disease among orthopedic conditions for which regenerative medicine therapies described in its consumer warning have not received approval.
Back pain is also not one diagnosis. Disc degeneration, herniation, spinal stenosis, muscular pain, joint problems, nerve compression, and other conditions can produce similar symptoms. An appropriate treatment for one cause may make little sense for another.
Patients researching regenerative options for a spine problem should first understand the underlying diagnosis. Our information on spine pain provides additional context about conditions that may need evaluation.
Claims such as “FDA compliant,” “uses your own cells,” or “performed in a medical office” should not be substituted for a clear answer about whether the particular product is FDA approved for the intended spinal condition.
Parkinson’s Disease and Neuropathy Require the Same Careful Distinction
FDA consumer guidance also states that regenerative medicine therapies have not been approved for neurological disorders such as Parkinson’s disease, multiple sclerosis, ALS, Alzheimer’s disease, epilepsy, or stroke.
Patients exploring Parkinson’s disease treatment options should therefore be cautious when a stem cell product is described as FDA approved unless the provider can identify the exact approved product and its approved indication.
Peripheral neuropathy requires similar care. Neuropathy can have different causes, and treatment decisions depend heavily on determining why the nerves are being affected. Patients researching the condition can review our peripheral neuropathy information before discussing treatment choices with a physician.
The existence of FDA-approved cell and gene therapies for certain rare neurological or genetic disorders does not mean that an unrelated stem cell product is approved for Parkinson’s disease or peripheral neuropathy. FDA approval does not transfer from one disease to another simply because both treatments involve cells.
Exosome FDA Approval Is Another Area Where Wording Matters
Exosomes are frequently discussed alongside stem cells and regenerative medicine, but they are not interchangeable with stem cells.
FDA’s consumer alert states that exosome products intended to treat diseases generally require FDA approval and that no FDA-approved exosome products were available when the alert was issued. FDA enforcement activity has continued more recently. In 2026, FDA warning letters again addressed products marketed as exosome therapies and identified products being marketed without required approval or licensure.
Patients should therefore be skeptical of phrases such as “FDA registered exosomes,” “research-grade exosomes,” or similar wording when those phrases are presented as if they establish approval for treating a disease.
The practical question remains the same: What is the exact product, and what specific FDA authorization or approval applies to its use for this condition?
Using Your Own Cells Does Not Automatically Make a Treatment FDA Approved
Another common misunderstanding involves autologous treatments, meaning cells or tissues obtained from and returned to the same patient.
A product does not automatically become FDA approved, exempt from FDA oversight, or proven effective merely because it came from the patient’s own body. FDA’s patient guidance specifically discusses unapproved regenerative medicine products obtained from either the patient’s own body or another person’s body.
The regulatory analysis can depend on factors such as what tissue is collected, how it is processed, how much manipulation occurs, what the resulting material is intended to do, and whether a regulatory exception applies. FDA guidance gives particular attention to concepts such as minimal manipulation and homologous use.
Bone marrow aspirate concentrate is one example patients may encounter in orthopedic discussions. Anyone researching BMAC therapy in Dallas should distinguish between the procedure being discussed, any devices used during processing, the biological material itself, and claims that the treatment is FDA approved.
Those are not automatically the same thing.
Clinical Trials and INDs Are Not the Same as Approval
Clinical research is how investigational treatments can be studied before approval, but participation in research should not be confused with receiving an approved treatment.
FDA explains that regenerative medicine products requiring approval generally need FDA oversight through an appropriate clinical trial before approval. The agency also warns that being listed on ClinicalTrials.gov does not prove that a product is legally marketed or FDA approved.
An IND can allow an investigational product to be administered as part of research under FDA oversight. That status means the treatment is being investigated. It does not mean FDA has already concluded that the treatment is safe and effective for routine commercial use.
A patient who is told that a treatment is part of a clinical trial can reasonably ask for the study identifier, the responsible investigator, the informed consent documents, the IND information where applicable, and an explanation of who is paying for treatment-related expenses.
What Should Dallas Patients Ask Before Paying for Treatment?
The safest way to evaluate a regenerative medicine claim is to make the clinic become specific.
| Question | Why It Matters |
|---|---|
| What exactly is being administered? | “Stem cells” can refer to very different materials. Ask for the product name, source, manufacturer, and how it is prepared. |
| Are the cells from my body or a donor? | Autologous and donor-derived materials can fall under different practical and regulatory considerations. |
| Is this exact product FDA approved? | General statements about FDA registration or laboratory standards do not answer this question. |
| What condition is it approved to treat? | Approval for one indication does not establish approval for knee pain, back pain, Parkinson’s disease, or neuropathy. |
| If it is investigational, is there an IND? | An IND may indicate FDA oversight of research, but it is not marketing approval. |
| What evidence supports this use? | Ask whether evidence comes from controlled clinical trials, observational studies, laboratory work, or testimonials. These forms of evidence are not equivalent. |
| What are the known and uncertain risks? | FDA has reported serious adverse events involving some unapproved regenerative products. |
| What alternatives should I consider? | A balanced discussion should include established treatments, watchful waiting where appropriate, rehabilitation, medications, procedures, or surgery depending on the diagnosis. |
| What is the complete cost? | Ask for the total expected price, follow-up costs, repeat treatment costs, and management of complications before paying. |
| What happens if the treatment does not help? | Patients should understand follow-up plans rather than assuming improvement is guaranteed. |
FDA has reported adverse events associated with unapproved regenerative medicine products, including serious infections, unwanted inflammatory or immune reactions, neurological events, tumor formation, and blindness. These reports do not mean every cell-based procedure causes these complications, but they are a reason to evaluate product source, processing, evidence, and regulatory status carefully.
FDA also continued enforcement activity against certain marketed stem cell, cord tissue, and exosome products in 2026, which shows that regulatory scrutiny in this area remains active.
Evidence Quality Matters as Much as Regulatory Status
FDA approval answers an important regulatory question, but it is not the only question a patient should ask.
A treatment may be under legitimate investigation without being approved. Conversely, scientific interest in a biological mechanism does not prove that a particular commercial treatment improves patient outcomes.
Look closely at what the evidence actually measures. Laboratory findings, animal research, early human studies, uncontrolled case series, randomized trials, and long-term clinical evidence provide different levels of information. Testimonials can describe individual experiences, but they cannot establish how reliably a treatment works or whether improvement came from the treatment itself.
Patients comparing conditions and treatment categories can use the Conditions We See resource as a starting point for understanding which diagnosis should be evaluated before discussing a procedure.
A credible medical conversation should also include uncertainty. If the evidence is limited, investigational, conflicting, or specific to a narrow patient group, that should be explained plainly.
When Established Care May Be the Better Next Step
Interest in regenerative medicine should not delay evaluation of a condition that may respond better to established treatment.
For orthopedic problems, the appropriate next step depends on the diagnosis, severity, functional limitations, examination findings, imaging, previous treatment, and the patient’s goals. Some people may be managed conservatively. Others may eventually need a procedure or surgery. No regenerative treatment should be assumed to eliminate those possibilities before a proper evaluation.
Neurological conditions deserve similar caution. Parkinson’s disease, peripheral neuropathy, multiple sclerosis, stroke, and other neurological disorders have different causes and treatment pathways. An investigational regenerative product should not automatically replace established neurological care.
Patients should also be wary when a consultation presents only one treatment, dismisses reasonable alternatives, guarantees tissue regeneration, promises that surgery will definitely be avoided, or describes an investigational product as a proven cure.
The purpose of discussing FDA status is not to tell every patient what treatment to choose. It is to make sure that the decision is based on accurate information.
Talk With a Physician About Your Options
If you’re considering stem cell therapy, BMAC, exosomes, or another regenerative treatment in Dallas, ask for the exact product, its source, its regulatory status, the evidence supporting the proposed use, known risks, realistic alternatives, and the complete expected cost.
FDA approval should never be assumed from words such as “registered,” “compliant,” “clinical trial,” or “uses your own cells.”
A physician familiar with your diagnosis can help you compare those facts with established treatment options and determine what questions still need answers.